Drug Database
OX

oxybutynin (oxybutynin, TIMERx / Ditropan CR / Cystrin CR)

✓ Approved

Takeda · CHRM1 · 小分子

什么是 oxybutynin?

oxybutynin 是一种小分子,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名oxybutynin, TIMERx, Ditropan CR, Cystrin CR
公司Takeda
药物类别小分子
分子靶点CHRM1, CHRM2, CHRM3, CHRM4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

oxybutynin 作用于 4 个分子靶点:

CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

oxybutynin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Renal and urinary disordersUrinary incontinence✓ Approved

相关研究文献

PubMedGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2026-11-18

Non-hormonal management of menopause symptoms-the statement of the European Society of Gynecology.

Castelo-Branco Camil C, Kiesel Ludwig L, Yoldemir Tevfik T, Chabbert-Buffet Nathalie N et al.

Menopausal symptoms, particularly vasomotor symptoms (VMS), sleep disturbances, mood disorders, and genitourinary syndrome of menopause (GSM), affect a substantial proportion of women and may significantly impair the quality of life. Although menopausal hormone therapy (MHT) remains the most effective treatment, many women have contraindications to hormonal treatment or prefer non-hormonal options. To review and provide evidence-based recommendations on current non-hormonal interventions for the management of menopausal symptoms. The European Society of Gynecology convened an expert panel that performed a comprehensive literature review using MEDLINE and EMBASE. Clinical guidelines, systematic reviews, meta-analyzes, randomized controlled trials, and relevant primary studies evaluating non-hormonal interventions for menopausal symptoms were identified, critically appraised, and synthesized through a structured consensus process. Lifestyle modification, including healthy diet, regular physical activity, weight control, sleep hygiene, and behavioral interventions, forms the foundation of menopausal care. Among pharmacological therapies, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, clonidine, oxybutynin, and pregabalin demonstrate varying degrees of efficacy for VMS. Neurokinin receptor antagonists, particularly fezolinetant and elinzanetant, represent the most effective evidence-based non-hormonal pharmacologic therapies currently available. Cognitive behavioral therapy and clinical hypnosis effectively reduce VMS-related distress and improve sleep and quality of life. Evidence for complementary approaches such as mindfulness, yoga, acupuncture, acupressure, reflexology, phytoestrogens, S-equol, DT56a, purified pollen extracts, and black cohosh ranges from moderate to limited. For GSM, lubricants, moisturizers, hyaluronic acid preparations, and pelvic floor muscle training provide symptomatic benefit, whereas current evidence does not support routine use of vaginal laser therapy. Non-hormonal therapies provide effective and individualized treatment options for menopausal symptoms, particularly for women who are unable or unwilling to use MHT. Neurokinin receptor antagonists, selected pharmacologic agents, psychological interventions, and targeted GSM therapies represent the strongest evidence-based approaches currently available. The choice of treatment should consider symptom profile, contraindications, adverse effects, regulatory approval, and patient preferences.

PMID 43049482
阅读全文 →
PubMedSleep medicine2026-11-17

Effects of pharmacotherapy on quantitative electroencephalogram measures of sleepiness in obstructive sleep apnea.

Tan Clara J E CJE, Altree Thomas J TJ, D'Rozario Angela L AL, Eckert Danny J DJ et al.

Recent studies of noradrenergic and antimuscarinic agents to treat obstructive sleep apnoea (OSA) have been promising, but their impact on subjective and objective sleep quality and daytime sleepiness have shown inconsistent results. This study aimed to assess the effects of the noradrenergic agent reboxetine alone and in combination with the antimuscarinic oxybutynin on next-day objective sleepiness through quantitative analysis of wake electroencephalography (qEEG) during a Karolinska Drowsiness Test (KDT). This was a secondary analysis from a randomised trial of reboxetine alone and in combination with oxybutynin versus placebo in 16 participants with OSA. All participates have undergone a KDT in the evening prior to drug or placebo administration and sleep opportunity, and ∼1hr post-waking next morning. Mixed models were used to examine drug effects on qEEG outcomes. There was no significant main effect of treatment (Reboxetine vs placebo vs Reboxetine-Oxybutynin) on slow EEG frequencies or theta/alpha ratio during the morning KDT. There was a significant main effect of testing time (evening vs morning) with higher morning delta and theta EEG power during eyes open and the delta power during entire KDT (all p < 0.001) compared to the evening test. There was a significant main effect of electrode position (F3, C3, O1), on wake delta and theta EEG with both frequencies higher in frontal (F3) vs occipital regions (O1) (all p < 0.001). There were no interaction effects and no correlations between qEEG outcomes and morning subjective sleepiness. Reboxetine with and without oxybutynin did not increase neurophysiological markers of next-day morning sleepiness as measured by wake delta and theta EEG power. These findings support the potential safety profile of these agents in respect to next-day sleepiness in people with OSA.

PMID 43044485
阅读全文 →
PubMedAAPS PharmSciTech2026-11-10

Paralleled Polymer Degradation and Oxybutynin Release from Short-Chain Polyesters for In-Situ Forming Intravesical Implant Design.

Hartig Michael Uwe MU, Appelhaus Jan J, Crombach Lukas Felix LF, Vollenbröker Marc M et al.

In situ forming implants (ISFI) for intravesical drug delivery represent a promising alternative to current treatment options for neurogenic detrusor overactivity (NDO). Previous formulations demonstrated opportunities for further optimization regarding the temporal alignment between drug release and polymer degradation, which may influence depot persistence during repeated administration. Therefore, different polyester grades with various molecular weights and solvent systems were investigated in order to parallel drug release and polymer degradation. Reducing the molecular weight from 38 to 2 kDa increased degradation threefold (from 8 to 25% within 72 h). Nevertheless, ISFI with PLGA 2 k were characterized by a high initial drug release of 20% after 24 h. By an increase of application frequency from once every nine days to every third day, the initial drug release was reduced to 10% within the first three days paralleling drug release and polymer degradation (10% after 72 h), resulting in a nearly linear relationship between these processes. These findings demonstrate that dose-splitting can effectively modulate release kinetics, supporting improved temporal alignment of drug release and polymer degradation without substantially increasing burst release. In addition, with a low molecular weight polyester grade, depot persistence may be further reduced under repeated administration conditions. Still, an ISFI administered every three days can distinctly improve the quality of life for NDO patients currently administering up to five doses daily.

PMID 43004078
阅读全文 →
PubMedCureus2026-11-09

Management of Vasomotor Symptoms in Women With Breast Cancer: From Pathophysiology to the Emerging Role of Neurokinin Receptor Antagonism.

Bimpa Kanelina K, Emmanouil Vasileios V, Xydias Emmanouil M EM, Varvaras Dimitrios D et al.

Vasomotor symptoms (VMS), encompassing hot flashes and night sweats, are among the most frequent and disruptive consequences of estrogen withdrawal in women with breast cancer. In this population, menopause may occur naturally or in association with cancer treatment, while the use of menopausal hormone therapy (MHT) is limited by concerns regarding oncological safety. The present narrative review synthesizes current understanding of the neuroendocrine pathophysiology of vasomotor symptoms, centered on the hypertrophy and hyperactivity of hypothalamic neurons co-expressing kisspeptin, neurokinin B (NKB), and dynorphin (KNDy) following estrogen deprivation, and critically appraises the available non-hormonal management options, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, oxybutynin, and cognitive behavioral therapy (CBT). Particular emphasis is placed on the neurokinin receptor antagonists, a mechanistically targeted drug class that acts on the thermoregulatory pathways involved in VMS. Fezolinetant is a selective neurokinin-3 receptor antagonist evaluated in the SKYLIGHT program, while elinzanetant is a dual neurokinin-1 and neurokinin-3 receptor antagonist evaluated in the OASIS program, including a pivotal placebo-controlled trial in women experiencing vasomotor symptoms associated with endocrine therapy for breast cancer. Dedicated studies of fezolinetant in women with breast cancer are ongoing. Neurokinin receptor antagonism represents a promising non-hormonal therapeutic strategy for VMS in this population, although agent-specific safety considerations and the need for longer-term oncological safety data require further evaluation.

PMID 43001086
阅读全文 →
PubMedTranslational andrology and urology2026-11-08

Oxybutynin for hot flashes in men on androgen-deprivation therapy: interpreting the Alliance A222001 trial.

Greenstein Adam A, Vassallo Mauricio M, Jabalameli Navid N, Rais-Bahrami Soroush S

PMID 42997252
阅读全文 →
PubMedJAMA network open2026-11-06

Drug Therapies and Incidence of Dementia Among Adults With Overactive Bladder.

Sheyn David D, Rhodes Stephen S, Mohamed Zeinab Z, Hijaz Adonis A

Concern that anticholinergic medications for overactive bladder (OAB) are associated with increased dementia risk has encouraged a shift toward β3 adrenergic agonists, which are presumed cognitively safer. Whether this presumption is justified is uncertain. To compare the risk of incident dementia among adults initiating high-risk anticholinergic, low-risk anticholinergic, or β3 agonist therapy for OAB and to evaluate the association of treatment duration with risk. This retrospective cohort study used Epic Cosmos electronic health record data from 2012 to 2025. Adults aged 40 to 90 years newly treated for OAB within 1 year of diagnosis without preexisting dementia were included. First prescribed medication class: high-risk anticholinergics (oxybutynin, tolterodine, or solifenacin), low-risk anticholinergics (darifenacin, trospium, or fesoterodine), or β3 agonists (mirabegron or vibegron). Incident dementia by diagnosis code or dementia-specific medication. Inverse probability of treatment weighting (IPTW) and Cox proportional hazards models were used, with analyses stratified by age and sex and an exploratory landmark duration-response analysis. Among 830 393 patients (585 198 female [70.5%]; median [IQR] age, 67 [57-76] years), incident dementia occurred in 65 134 patients, with a median (IQR) follow-up ranging from 1046 (571-1809) days for β3 agonists to 1568 (857-2614) days for high-risk anticholinergics. After IPTW, high-risk anticholinergics were associated with a lower hazard of dementia than β3 agonists (hazard ratio [HR], 0.90; 95% CI, 0.87-0.93) and low-risk anticholinergics (HR, 0.93; 95% CI, 0.90-0.96); low-risk anticholinergics did not differ from β3 agonists (HR, 0.97; 95% CI, 0.93-1.01). Weighted 10-year dementia risk was highest for β3 agonists (20.0%; 95% CI, 18.8%-21.2%) and lowest for high-risk anticholinergics (18.1%; 95% CI, 17.9%-18.3%). E-values of 1.29 (high-risk anticholinergics vs β3 agonists) and 1.20 (high-risk vs low-risk anticholinergics) suggested that observed differences could be explained by a modest amount of unmeasured confounding. Longer anticholinergic duration was not associated with increased risk. In this cohort study of patients undergoing treatment for OAB, β3 agonists were not associated with a lower dementia incidence compared with anticholinergics. These findings suggest that previously reported increases in risk may reflect residual confounding rather than a pharmacological effect.

PMID 42993548
阅读全文 →

注册免费账户还可查看另外 1615 篇文献

免费注册查看全部文献 →

了解更多oxybutynin